Carnitine Deficiency in Chinese Children with Epilepsy on Valproate Monotherapy

Area of Science:

• Biochemistry
• Pediatric Neurology
• Clinical Pharmacology

Background:

• Epilepsy is a common neurological disorder in children.
• Valproate is a widely used antiepileptic drug.
• Secondary carnitine deficiency is a potential adverse effect of valproate therapy.

Purpose of the Study:

• To determine the incidence of secondary carnitine deficiency in Chinese children with epilepsy on valproate monotherapy.
• To identify independent risk factors associated with this deficiency.

Main Methods:

• A comparative study involving 299 children with epilepsy on valproate monotherapy and 299 age- and sex-matched healthy controls.
• Measurement of free carnitine and acylcarnitines levels.
• Statistical analysis to identify independent risk factors.

Main Results:

• Children on valproate showed significantly lower free carnitine levels compared to controls (23.86 vs. 36.37 µmol/L).
• Carnitine deficiency was observed in 21.1% of children on valproate, with most cases being asymptomatic.
• Independent risk factors identified were female gender (OR 2.1), high alanine aminotransferase levels (OR 1.0), and duration of valproate treatment between 1-12 months (OR 1.9).

Conclusions:

• Secondary carnitine deficiency is prevalent in Chinese children with epilepsy treated with valproate.
• Female patients, those with elevated liver enzymes, and those treated for 1-12 months are at higher risk.